Enloplatin
Clinical data
Other namesEnloplatine, enloplatino, enloplatinum
Pharmacokinetic data
Bioavailability100% (IV)
Protein binding> 85%
Elimination half-life56±40 hours (Whole blood)
52±40 hours (Blood plasma)[1]
ExcretionRenal
Identifiers
  • [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+)
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H20N2O5Pt
Molar mass479.396 g·mol−1
3D model (JSmol)
Melting point260 to 263[2] °C (500 to 505 °F)
Solubility in water450[lower-alpha 1] mg/mL (20 °C)
  • C1CC(C1)(C(=O)[O-])C(=O)[O-].C1COCCC1(C[NH-])C[NH-].[Pt+4]
  • InChI=1S/C7H14N2O.C6H8O4.Pt/c8-5-7(6-9)1-3-10-4-2-7;7-4(8)6(5(9)10)2-1-3-6;/h8-9H,1-6H2;1-3H2,(H,7,8)(H,9,10);/q-2;;+4/p-2
  • Key:NAFFDQVVNWTDJD-UHFFFAOYSA-L

Enloplatin is a water-soluble cancer medication. It is a platinum-based antineoplastic investigated for treatment of platinum-refractory ovarian cancer, in which it was demonstrated to have minimal activity.[3] This cancer is suspected to be at least partially cross-resistant with another third-generation platinum analog, zeniplatin, which also shows minimal antitumor activity in this type of cancer. It was found to be cross-resistant with carboplatin.[1]

Like zeniplatin and carboplatin, use of enloplatin causes manageable nephrotoxicity, no significant neurotoxicity or ototoxicity, and dose-limiting myelosuppression.[1]

The drug was original developed by Wyeth, but no further development since 2000 has been reported.[4]

Structure

Ball-and-stick model of enloplatin

Like any platinum-based antineoplastic drug enloplatin is a coordination complex of platinum. Its two bidentate ligands are a tetrahydropyran-containing amine and cyclobutane dicarboxylic acid (CBDCA). Its CBDCA ligand is identical to that of carboplatin. It was found to have similar pharmokinetics to carboplatin, indicating it is the CBDCA ligand and not the amine that most influences plasma pharmokinetics of these platinum complexes.[1]

Notes

  1. ↑ As hydrate.

References

  1. 1 2 3 4 Kudelka AP, Siddik ZH, Tresukosol D, Edwards CL, Freedman RS, Madden TL, et al. (August 1997). "A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma". Anti-Cancer Drugs. Ovid Technologies (Wolters Kluwer Health). 8 (7): 649–656. doi:10.1097/00001813-199708000-00001. PMID 9311439. S2CID 46635787.
  2. ↑ Bitha P, Carvajal SG, Citarella RV, Child RG, Delos Santos EF, Dunne TS, et al. (August 1989). "Water-soluble third generation antitumor platinum complexes, [2,2-bis (aminomethyl)-1,3-propanediol-N,N']-[1,1-cyclobutanedicarboxylato (2-)-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'] [tetrahydro-4H-pyran-4,4-dimethanamine-N,N']platinum(II)". Journal of Medicinal Chemistry. American Chemical Society (ACS). 32 (8): 2015–2020. doi:10.1021/jm00128a052. PMID 2754720.
  3. ↑ Amorusi P, Lessard D, Bansal SK, Selinger K, Yacobi A, Tonelli AP (August 1994). "Analysis of enloplatin by liquid chromatography and of platinum by atomic absorption spectrometry in various biological fluids". Journal of Pharmaceutical and Biomedical Analysis. Elsevier BV. 12 (8): 1023–1033. doi:10.1016/0731-7085(94)e0035-y. PMID 7819376.
  4. ↑ "Enloplatin". AdisInsight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.